Targeted therapy for brain metastases: improving the therapeutic ratio.
Brain metastasis is the most common intracranial malignancy in adults. Improvements in modern imaging techniques are detecting previously occult brain metastases, and more effective therapies are extending the survival of patients with invasive cancer who have historically died from extracranial disease before developing brain metastasis. This combination of factors along with increased life expectancy has led to the increased diagnosis of brain metastases. Conventional treatment has been whole brain radiotherapy, which can improve symptoms, but potentially results in neurocognitive deficits. Several strategies to improve the therapeutic ratio are currently under investigation to either enhance the radiation effect, thereby preventing tumor recurrence or progression as well as reducing collateral treatment-related brain injury. In this review article, we discuss new directions in the management of brain metastases, including the role of chemical modifiers, novel systemic agents, and the management and prevention of neurocognitive deficits.
Patel
Rakesh R
RR
Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA. patel@humonc.wisc.edu
Mehta
Minesh P
MP
D001932:Brain Neoplasms / Q000150:complications / Q000517:prevention & control / Q000556:secondary* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003072:Cognition Disorders / Q000209:etiology; D018450:Disease Progression; D006801:Humans; D011832:Radiation Injuries / Q000517:prevention & control; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome
D011838:Radiation-Sensitizing Agents